Variables associated with alcohol, drug, and daily smoking cessation in patients with severe mental illnesses

Journal of Clinical Psychiatry

Volumn 66, Issue 11, 2005, Pages 1447-1455

  De Leon, Jose ^a   Susce, Margaret T ^a   Diaz, Francisco J ^b   Rendon, Diego M ^b   Velásquez, Diana M ^b  

^a Eastern State Hospital   (United States)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

ADULT; ALCOHOLISM; ARTICLE; CIGARETTE SMOKING; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABUSE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH CENTER; OBESITY; OUTPATIENT; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SMOKING CESSATION;

EID: 28844478483     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1112     Document Type: Article

References (56)

1. Gonzalez JJ, Insel TR. The conundrum of co-occurring mental and substance use disorders: opportunities for research. Biol Psychiatry 2004;56:723-725
2. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000;26:105-118
3. Mark T. The costs of treating persons with depression and alcoholism compared with depression alone. Psychiatr Serv 2003:54:1095-1097
4. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-2518
5. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-2610
6. Classman AH. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993:150:546-553
7. Gonzalez-Pinto A, Gutierrez M, Ezcurra J, et al. Tobacco smoking and bipolar disorder. J Clin Psychiatry 1998;59:225-228
8. de Leon J, Becoña E, Guipegui M, et al. The association between high nicotine dependence and severe mental illness may be consistent across countries. J Clin Psychiatry 2002;63:812-816
9. Grant BF, Hasin DS, Chou SP, et al. Nicotine dependence and psychiatrie disorders in the United States. Arch Gen Psychiatry 2004;61:1107-1115
10. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005;76:135-157
11. Gurpegui M, Martinez-Ortega JM, Aguilar MC, et al. Smoking initiation and schizophrenia: a replication study in a Spanish sample. Schizophr Res 2005;76:113-118
12. de Leon J, Diaz FJ, Rogers T, et al. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002;56:47-54
13. de Leon J, Dadvand M, Canuso C, et al. Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995;152:453-155
14. de Leon J, Tracy J, McCann E, et al. Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 2002;56:55-65
15. LLerena A, de la Rubia A, Penas-Lledo EM, et al. Schizophrenia and tobacco smoking in a Spanish psychiatric hospital. Schizophr Res 2003;60:313-317
16. Diwan A, Castine M, Pomerlau C, et al. Different prevalence of cigarette smoking in patients with schizophrenia vs mood disorders. Schizophr Res 1998;33:113-118
17. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav 1998;23:717-734
18. Kessler R. Impact of substance abuse on the diagnosis, course, and treatment of mood disorders: the epidemiology of dual diagnosis. Biol Psychiatry 2004;56:730-737
19. Phillips P, Johnson S. How does drug and alcohol misuse develop among people with psychotic illness? a literature review. Soc Psychiatry Psychiatr Epidemiol 2001;36:269-276
20. Kendler KS, Neale MC, MacLean CJ, et al. Smoking and major depression: a causal analysis. Arch Gen Psychiatry 1993;50:36-43
21. de Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996;22:405-409
22. Freedman R, Coon H, Myles-Worsley M, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Nat Acad Sci U S A 1997;94:587-592
23. Drake RE, Mueser KT, Brunette MF, et al. A review of treatments for people with SMIs and co-occurring substance use disorders. Psychiatr Rehabil J 2004;27:360-374
24. Ziedonis DM. Integrated treatment of co-occuring mental illness and addiction: clinical intervention, program, and system perspectives. CNS Spectrums 2004;9:892-904
25. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743-755
26. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). Am J Psychiatry 2000;157(suppl 4):l-45
27. Lehman AF, Lieberman JA, Dixon LB, et al. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry 2004;161(suppl 2):1-56
28. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994;151(suppl 12):1-36
29. McChargue DE, Gulliver SB, Hitsman B. Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction 2002;97:785-793
30. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27
31. Susce MT, Villanueva N, Diaz FJ, et al. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 2005;66:167-173
32. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005;25:448-456
33. Mueser KT, Drake RE, Clark RE, et al. Toolkit on Evaluating Substance Abuse in Persons With Severe Mental Illness. Cambridge, Mass: The Evaluation Center at Human Services Research Institute; 1995
34. Norusis MJ. SPSS Professional Statistics 7.5. Chicago, Ill: SPSS Inc; 1997
35. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons Inc; 2000
36. Brunette MF, Drake RE Gender differences in patients with schizophrenia and substance abuse. Compr Psychiatry 1997;38:109-116
37. Vega WA, Aguilar-Gaxiola S, Andrade L, et al. Prevalence of age of onset for drug use in 7 international sites: results from the International Consortium of Psychiatry Epidemiology. Drug Alcohol Depend 2002;68:285-297
38. Warner LA, Kessler RC, Hughes M, et al. Prevalence and correlates of drug use and dependence in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1995;52:219-229
39. Glassman AH, Covel LS, Stetner F, et al. Smoking cessation and the course of major depression. Lancet 2001;357:1929-1931
40. Salin-Pascual RJ, Rosas M, Jiménez-Genchi A, et al. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry 1996;57:387-389
41. Aguilar MC, Gurpegui M, Diaz FJ, et al. Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions. Br J Psychiatry 2005;186:225-231
42. Graeber DA, Moyers TB, Griffith G, et al. A pilot study comparing motivational interviewing and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J 2003;39:189-202
43. Martino S, Carroll KM, Kostas D, et al. Dual diagnosis motivational interviewing: A modification of motivational interviewing for substance-abusing patients with psychotic disorders. J Subst Abuse Treat 2002;23:297-308
44. Martino S, Carroll KM, O'Malley SS, et al. Motivational interviewing with psychiatrically ill substance abusing patients. Am J Addict 2000;9:88-91
45. Miller WR, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd Ed. New York, NY: Guilford Press; 2002
46. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology 2004;174:54-64
47. Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behavior. Br J Psychiatry 2000;176:345-350
48. Brown S, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217
49. Dickey B, Normand ST, Weiss RD, et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv 2002;53:861-867
50. Prochaska JJ, Gill P, Hall SM. Treatment of tobacco use in an inpatient psychiatric setting. Psychiatric Serv 2004;55:1265-1270
51. de Leon J. Psychopharmacology: atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004;55:491-493
52. Pinninti NR, Mago R, de Leon J. Coffee, cigarettes, and meds: what are the metabolic effects? Psychiatr Times 2005;22:20-23
53. Ghisays RH, Gomez CA, Campo A, et al. Prevalencia de tabaquismo en pacientes de la consulta psiquiátrica. Biomédica 1996;16:52-57
54. Gurpegui M, Aguilar MC, Martinez-Ortega JM, et al. Caffeine intake in outpatients with schizophrenia. Schizophr Bull 2004;30:935-945
55. Uzun O, Cansever A, Basoglu C, et al. Smoking and substance abuse in outpatients with schizophrenia: a 2-year follow-up study in Turkey. Drug Alcohol Depend 2003;70:187-192
56. Leach RC. Kentucky Behavioral Risk Factor Surveillance System. 2001 Report. Frankfort, Ky: Kentucky Department for Public Health, Division of Epidemiology and Health Planning; June 2003. Available at: www.chs.ky.gov/ publichealth/BRFSS/2001. Accessed Jan 4, 2005